GeoVax company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

geovax.com

Founded Year

1988

Stage

PIPE | IPO

Market Cap

0.01B

About GeoVax

GeoVax is developing HIV (Human Immunodeficiency Virus) vaccines for prevention of AIDS in the worldwide human population.

GeoVax Headquarter Location

1900 Lake Park Drive Suite 38-

Smyrna, Georgia, 30080,

United States

(678) 384-7220

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

GeoVax Patents

GeoVax has filed 12 patents.

The 3 most popular patent topics include:

  • Vaccines
  • Animal viral diseases
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/18/2018

4/26/2022

Plasmodium, Vaccines, Malaria, Transcription factors, Animal viral diseases

Grant

Application Date

9/18/2018

Grant Date

4/26/2022

Title

Related Topics

Plasmodium, Vaccines, Malaria, Transcription factors, Animal viral diseases

Status

Grant

Latest GeoVax News

Phase 2 trial to assess investigational COVID-19 vaccine for individuals with cancer

May 5, 2022

Healio Interview Disclosures: Diamond reports a consulting role with GeoVax Labs, Inc. GeoVax Labs, Inc. has licensed COH04S1, and the accompanied platform that is used, as the exclusive licensee. City of Hope receives upfront payments, royalties and funding through clinical trial agreements. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio An investigational COVID-19 vaccine developed by City of Hope induced a robust immune response against SARS-CoV-2, according to results of a phase 1 clinical trial. In addition, researchers observed no significant adverse events. The findings — published in The Lancet Microbe — support advancing the vaccine into phase 2 testing specifically for immunocompromised individuals with cancer, according to investigators. Healio spoke with lead vaccine developer Don Diamond, PhD, about the efficacy and safety observed so far, the next steps in research, and the potential benefits this vaccine could provide to patients with cancer. Reference:

GeoVax Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

GeoVax Rank

  • When was GeoVax founded?

    GeoVax was founded in 1988.

  • Where is GeoVax's headquarters?

    GeoVax's headquarters is located at 1900 Lake Park Drive, Smyrna.

  • What is GeoVax's latest funding round?

    GeoVax's latest funding round is PIPE.

  • Who are the investors of GeoVax?

    Investors of GeoVax include Armistice Capital, Emory University and Emtech Bio.

  • Who are GeoVax's competitors?

    Competitors of GeoVax include Merus, CoImmune, Humanetics Corporation, Profectus BioSciences, Tobira Therapeutics and 12 more.

You May Also Like

P
Panacos Pharmaceuticals

Panacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.

P
Profectus BioSciences

Profectus Biosciences is a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases. The Company's name, Profectus, when translated from its Latin roots, means"to advance or improve". The Company's proof of concept target is human immunodeficiency virus (HIV) with an intermediate term focus on hepatitis C virus (HCV).

P
Photopharmica

Photopharmica, developing light sensitive drugs for the prevention and treatment of diseases in the anti-infective and oncology markets photosensitisers, for industrial applications

O
Opal Therapeutics

Opal Therapeutics is an immunotherapy company focused on therapies for human immunodeficiency virus (HIV) and Hepatitis C (HCV), based on technology from the University of Melbourne.

K
Koronis Pharmaceuticals

Koronis Pharma develops antiviral therapeutics based on Viral Decay Acceleration, which exploits the strength of a virus to target its collapse.

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.